DSIJ Mindshare

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 0 167 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

DSIJ Intelligence-1 0 201 Article rating: 4.5

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why

The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.

DSIJ Intelligence-1 0 165 Article rating: 5.0

The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.

RSS
1345678910Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR